Modification of Clearview Tuberculosis (TB) Enzyme-Linked Immunosorbent Assay for TB Patients Not Infected with HIV | Zendy

Laura Savolainen | Zendy; Anu Kantele | Zendy; Bettina Sandboge | Zendy; Marita Sirén | Zendy; Heikki Valleala | Zendy; Riitta Tuompo | Zendy; Liana Pusa | Zendy; R. ErkinjunttiPekkanen | Zendy; Aija Knuuttila | Zendy; ChengLung Ku | Zendy; Francesco Bianchi-Demicheli | Zendy; Tuula Vasankari | Zendy; Tamara Tuuminen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Modification of Clearview Tuberculosis (TB) Enzyme-Linked Immunosorbent Assay for TB Patients Not Infected with HIV

Author(s) -

Laura Savolainen,

Anu Kantele,

Bettina Sandboge,

Marita Sirén,

Heikki Valleala,

Riitta Tuompo,

Liana Pusa,

R. ErkinjunttiPekkanen,

Aija Knuuttila,

ChengLung Ku,

Francesco Bianchi-Demicheli,

Tuula Vasankari,

Tamara Tuuminen

Publication year - 2013

Publication title -

clinical and vaccine immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.649

H-Index - 77

eISSN - 1556-6811

pISSN - 1556-679X

DOI - 10.1128/cvi.00375-13

Subject(s) - lipoarabinomannan , medicine , urine , mycobacterium tuberculosis , tuberculosis , urinary system , university hospital , human immunodeficiency virus (hiv) , virology , immunology , pathology

Diagnosis of active tuberculosis by detection of urinary lipoarabinomannan (uLAM) from Mycobacterium tuberculosis is an attractive approach. Concentrating urine 100-fold allowed quantitation of uLAM at levels equal to picograms/ml of nonconcentrated urine. The approach of concentrating urine 100-fold improved the clinical sensitivity of the Clearview TB enzyme-linked immunosorbent assay (ELISA) from 7% to 57% yet impaired its specificity from 97% to 89%. (This study has been registered at University Hospital of Turku under registration no. 47/180/2009, Helsinki University Central Hospital under 149/2010, University Hospital of Kuopio under 105/2010, and China Medical University Hospital, Taichung, under DMR-99-IRB-075-2.).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research